RT Journal Article
SR Electronic
T1 Aerosolized Ad5-nCoV booster vaccination elicited potent immune response against the SARS-CoV-2 Omicron variant after inactivated COVID-19 vaccine priming
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.08.22271816
DO 10.1101/2022.03.08.22271816
A1 Zhang, Zhe
A1 Wu, Shipo
A1 Liu, Yawei
A1 Li, Kailiang
A1 Fan, Pengfei
A1 Song, Xiaohong
A1 Wang, Yudong
A1 Zhao, Zhenghao
A1 Zhang, Xianwei
A1 Shang, Jin
A1 Zhang, Jinlong
A1 Xu, Jinghan
A1 Li, Yao
A1 Li, Yaohui
A1 Zhang, Jipeng
A1 Fu, Kefan
A1 Wang, Busen
A1 Hao, Meng
A1 Zhang, Guanying
A1 Long, Pengwei
A1 Qiu, Ziyu
A1 Zhu, Tao
A1 Liu, Shuling
A1 Zhang, Yue
A1 Shao, Fangze
A1 Lv, Peng
A1 Yang, Yilong
A1 Zhao, Xiaofan
A1 Sun, Yufa
A1 Hou, Lihua
A1 Chen, Wei
YR 2022
UL http://medrxiv.org/content/early/2022/03/10/2022.03.08.22271816.abstract
AB The SARS-CoV-2 Omicron variant has become the dominant SARS-CoV-2 variant around the world and exhibits immune escape to current COVID-19 vaccines to some extent due to its numerous spike mutations. Here, we evaluated the immune responses to booster vaccination with intramuscular adenovirus-vectored vaccine (Ad5-nCoV), aerosolized Ad5-nCoV, a recombinant protein subunit vaccine (ZF2001) or homologous inactivated vaccine (CoronaVac) in those who received two doses of inactivated COVID-19 vaccines 6 months prior. We found that the Ad5-nCoV booster induced potent neutralizing activity against the wild-type virus and Omicron variant, while aerosolized Ad5-nCoV generated the greatest neutralizing antibody responses against the Omicron variant at day 28 after booster vaccination, at 14.1-fold that of CoronaVac, 5.6-fold that of ZF2001 and 2.0-fold that of intramuscular Ad5-nCoV. Similarly, the aerosolized Ad5-nCoV booster produced the greatest IFNγ T-cell response at day 14 after booster vaccination. The IFNγ T-cell response to aerosolized Ad5-nCoV was 12.8-fold for CoronaVac, 16.5-fold for ZF2001, and 5.0-fold for intramuscular Ad5-nCoV. Aerosolized Ad5-nCoV booster also produced the greatest spike-specific B cell response. Our findings suggest that inactivated vaccine recipients should consider adenovirus-vectored vaccine boosters in China and that aerosolized Ad5-nCoV may provide a more efficient alternative in response to the spread of the Omicron variant.Competing Interest StatementTao Zhu is the employee of CanSino Biologics and has stock options in CanSino Biologics. All other authors declare no competing interests.Clinical TrialChiCTR2200057278Funding StatementThis study was funded by the National Key R&D Program of ChinaAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Committee of 305 Hospital of PLA gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyoline (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors